Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$10M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$10M
- −45.5% YoY · −14.3% QoQ
- EPS (diluted)
- −$0.05
- +16.7% YoY · +0.0% QoQ
Source: XBRL data from the SELLAS Life Sciences Group, Inc. (SLS) Q2 2026 10-Q on SEC EDGAR. USD.
SELLAS Life Sciences Group, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged from $0 YoY; no product sales
- Net loss $9.6M vs $6.6M YoY; operating loss $10.6M vs $6.9M
- Research and development $6.3M vs $3.9M; SLS009 costs $1.7M, GPS costs $1.1M
- Cash and equivalents $138.3M plus restricted cash $0.1M; operating cash use $16.4M vs $16.4M
- Outlook: cash sufficient for at least twelve months; R&D expenses expected to increase with GPS and SLS009 trials
Risk Factors
- No material risk-factor changes disclosed from the 2025 Annual Report
- Clinical-development risk carried forward through reliance on successful trials and regulatory approvals
- Financing risk carried forward from continued dependence on additional capital to fund operations
- Stock-price risk heightened by directors’ Rule 10b5-1 plans covering 45,000 shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SELLAS Life Sciences Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.